These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 38688353

  • 41. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
    Hirsch EB, Brigman HV, Zucchi PC, Chen A, Anderson JC, Eliopoulos GM, Cheung N, Gilbertsen A, Hunter RC, Emery CL, Bias TE.
    J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
    [Abstract] [Full Text] [Related]

  • 42. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C, Freire S, Nordmann P, Poirel L.
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [Abstract] [Full Text] [Related]

  • 43. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

  • 44. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M, Pontikis K, Nitsotolis T, Poulakou G.
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
    [Abstract] [Full Text] [Related]

  • 45. In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.
    Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P.
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
    [Abstract] [Full Text] [Related]

  • 46. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.
    Bianco G, Boattini M, Comini S, Iannaccone M, Casale R, Allizond V, Barbui AM, Banche G, Cavallo R, Costa C.
    J Chemother; 2022 Sep; 34(5):302-310. PubMed ID: 35098907
    [Abstract] [Full Text] [Related]

  • 47. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, Dortet L.
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [Abstract] [Full Text] [Related]

  • 48. Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Zhanel GG, Mansour C, Mikolayanko S, Lawrence CK, Zelenitsky S, Ramirez D, Schweizer F, Bay D, Adam H, Lagacé-Wiens P, Walkty A, Irfan N, Clark N, Nicolau D, Tascini C, Karlowsky JA.
    Drugs; 2024 Oct; 84(10):1219-1250. PubMed ID: 39214942
    [Abstract] [Full Text] [Related]

  • 49. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V.
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [Abstract] [Full Text] [Related]

  • 50. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1704-1708. PubMed ID: 28369471
    [Abstract] [Full Text] [Related]

  • 51. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J, Asar L, Klupp EM, Both A, Rothe C, König C, Rohde H, Kluge S, Maurer FP.
    PLoS One; 2018 Jun 01; 13(4):e0195757. PubMed ID: 29649276
    [Abstract] [Full Text] [Related]

  • 52. Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates.
    Morrissey I, Hawser S, Kothari N, Dunkel N, Quevedo J, Belley A, Henriksen AS, Attwood M.
    J Glob Antimicrob Resist; 2024 Sep 01; 38():71-82. PubMed ID: 38723712
    [Abstract] [Full Text] [Related]

  • 53. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
    Stewart AG, Harris PNA, Chatfield MD, Littleford R, Paterson DL.
    Trials; 2021 Apr 22; 22(1):301. PubMed ID: 33888139
    [Abstract] [Full Text] [Related]

  • 54. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
    Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2013 Feb 22; 73(2):159-77. PubMed ID: 23371303
    [Abstract] [Full Text] [Related]

  • 55. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Diagn Microbiol Infect Dis; 2020 Mar 22; 96(3):114833. PubMed ID: 31924426
    [Abstract] [Full Text] [Related]

  • 56. Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.
    Ito CAS, Bail L, Arend LNVS, Silva KO, Michelotto SS, Nogueira KDS, Tuon FF.
    J Clin Microbiol; 2021 Nov 18; 59(12):e0153621. PubMed ID: 34586889
    [Abstract] [Full Text] [Related]

  • 57. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D, Stone GG.
    BMC Infect Dis; 2021 Jun 23; 21(1):600. PubMed ID: 34162341
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.
    Cruz-López F, Martínez-Meléndez A, Morfin-Otero R, Rodriguez-Noriega E, Maldonado-Garza HJ, Garza-González E.
    Front Cell Infect Microbiol; 2022 Jun 23; 12():884365. PubMed ID: 35669117
    [Abstract] [Full Text] [Related]

  • 59. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS, Gould IM, Lee WS, Hsueh PR, International Society of Antimicrobial Chemotherapy (ISAC).
    Drugs; 2019 May 23; 79(7):705-714. PubMed ID: 30972660
    [Abstract] [Full Text] [Related]

  • 60. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR, Chen WH, Luh KT.
    Int J Antimicrob Agents; 2005 Dec 23; 26(6):463-72. PubMed ID: 16280243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.